Eligard HCP Template Site

Menu

RELY ON THE DEPTH OF ELIGARD’S CONTROL

ELIGARD Atrigel™

depot formulation

Minimises the risk of potential progression*2

Atrigel™ Technology: Sustained testosterone
suppression at the molecular level:

controlled-release-symbol

CONTROLLED AND SUSTAINED RELEASE2

Read More
breakthrough-symbol

LESS THAN 1% BREAKTHROUGHS2

Read More
treatment-adherance-symbol

GREATER LIKELIHOOD OF TREATMENT ADHERENCE

Read More

*The EAU-recommended testosterone level is <20 ng/dL.3 This definition is important as better
results are repeatedly observed with lower testosterone levels compared to 50 ng/dL.4

ELIGARD offers controlled and sustained release
of leuprorelin acetate between injections2

Asset 16@2x
Not all ADT formulations are the same: different administration technologies can significantly alter pharmacokinetics and effectiveness5
Asset 17@2x
ELIGARD Atrigel™ technology consists of a soluble polymer that ensures a sustained and stable release of leuprorelin2

Mixture of solvent and leuprorelin molecules

Subcutaneous injection
The polymer solidifies on
contact with water molecules
in the dermis and forms a
solid in-situ depot
Asset 3@2x

Continuous and extended release of leuprorelin

ELIGARD AtrigelTM provides reliability
for you and your patients:

delayed-onset-symbol

Delayed onset
of CRPC2,4,6,7

By maintaining testosterone levels associated with improved patient outcomes.*
14-days-symbol

An additional 14 days of
testosterone suppression8

Maximising drug exposure

of leuprorelin8

subcutaneous-symbol

Subcutaneous injections lasting 1, 3, and 6 months2

By sustaining effectiveness to allow for convenient dosing flexibility2,9

*The EAU-recommended testosterone level is <20 ng/dL.3 This definition is important as better results are repeatedly
observed with lower testosterone levels compared to 50 ng/dL.4

ADT, androgen deprivation therapy; EAU, European Association of Urology; CRPC, castrate-resistant prostate cancer.

Long-term control with no breakthroughs

in over 99% of patients, reducing the potential risk of disease progression2

Once achieved, castration levels were maintained throughout the treatment with ELIGARD (testosterone breakthroughs in <1% of patients)2
Adapted from Tombal B, 2007.2

Delayed injections can lead to elevated testosterone and increased
risk of breakthroughs, which can impact progression and survival10

ELIGARD provides testosterone

suppression to <20ng/dL with
<1% of breakthroughs1,2,11–13

In a clinical study to investigate the impact of late dosing, ELIGARD demonstrated consistently lower rates of testosterone escape above 20 ng/dL vs Lupron (a US leuprolide formulation)5

US, United States.

Consider the importance of treatment adherence
for your prostate cancer patients:

21-51%

mean
non-adherence
rates

25–51% of prostate cancer patients prescribed oral therapies were found to not adhere to treatment*14

More than

40%

of men
over 65

More than 40% of men over 65 had poor or very poor adherence to prescribed oral ADT15

Injections may offer a distinct advantage
over oral medications in patients where
adherence is a potential concern16

*Reported mean non-adherence rates.
ADT, androgen deprivation therapy; sc, subcutaneous.

Find out how can
support you and your patients       

References
  1. ELIGARD SmPC. Latest version.
  2. Tombal B, et al. Eur Urol Suppl 2007;6:754–760.
  3. Cornford P, et al. EAU Guidelines. Edn. presented at EAU Paris April 2024. ISBN 978-94-92671-23-3.
  4. Shore ND, et al. BJU lnt. 2017;119(2):239–244.
  5. Crawford ED, et al. J Urol. 2021;205:554–560.
  6. Saltzstein D, et al. Ther Adv Urol. 2017;10(2):43–50.
  7. Pieczonka CM, et al. Rev Urol. 2018;20(2):63–68.
  8. Perez-Marrero R & Tyler RC. Expert Opin Pharmacother. 2004;5(2):447–457.
  1. Sartor O. Eur Urol Suppl. 2006;5:905–910.
  2. Sethi R & Sanfilippo N. Clin Interv Aging. 2009;4:259–267.
  3. Perez-Marrero R, et al. Clin Ther. 2002;24:1902–1914.
  4. Chu FM, et al. J Urol. 2002;168:1199–1203.
  5. Crawford ED, et al. J Urol. 2006;175:533–536.
  6. Higano CS, et al. J Urol. 2023;209(3):485–493.
  7. Grundmark B, et al. Eur J Clin Pharmacol. 2012;68(12):1619–1630.
  8. Fleshner NE, et al. Ther Adv Med Oncol. 2023;15:17588359231152845.

This website is intended for healthcare professionals only.

 

ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent
advanced prostate cancer and for the treatment of high-risk localised and locally
advanced hormone dependent prostate cancer in combination with radiotherapy.1

GL-ELIGA-0020 | July 2025 © 2025 Recordati

References
  1. ELIGARD SmPC. Latest version.
  2. Tombal B, et al. Eur Urol Suppl 2007;6:754–760.
  3. Cornford P, et al. EAU Guidelines. Edn. presented at EAU Paris April 2024. ISBN 978-94-92671-23-3.
  4. Shore ND, et al. BJU lnt. 2017;119(2):239–244.
  5. Crawford ED, et al. J Urol. 2021;205:554–560.
  6. Saltzstein D, et al. Ther Adv Urol. 2017;10(2):43–50.
  7. Pieczonka CM, et al. Rev Urol. 2018;20(2):63–68.
  8. Perez-Marrero R & Tyler RC. Expert Opin Pharmacother. 2004;5(2):447–457.
  1. Sartor O. Eur Urol Suppl. 2006;5:905–910.
  2. Sethi R & Sanfilippo N. Clin Interv Aging. 2009;4:259–267.
  3. Perez-Marrero R, et al. Clin Ther. 2002;24:1902–1914.
  4. Chu FM, et al. J Urol. 2002;168:1199–1203.
  5. Crawford ED, et al. J Urol. 2006;175:533–536.
  6. Higano CS, et al. J Urol. 2023;209(3):485–493.
  7. Grundmark B, et al. Eur J Clin Pharmacol. 2012;68(12):1619–1630.
  8. Fleshner NE, et al. Ther Adv Med Oncol. 2023;15:17588359231152845.

This website is intended for healthcare professionals only.

 

ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent
advanced prostate cancer and for the treatment of high-risk localised and locally
advanced hormone dependent prostate cancer in combination with radiotherapy.1

GL-ELIGA-0020 | July 2025 © 2025 Recordati